ASCENT-03
Moved Trodelvy into first-line use for triple-negative patients who cannot receive immunotherapy.
PFS 9.7 vs 6.9 months (HR 0.62); OS immature at first analysis. Led to 2026 FDA approval of first-line monotherapy. Sets up direct comparison with Dato-DXd (TROPION-Breast02) in the same population.
- Median 9.7 vs 6.9 months with Sacituzumab govitecan compared with Chemotherapy (TPC); about 2.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 38 percent lower chance of the event at any given time (hazard ratio 0.62, likely range 0.5 to 0.77).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 48 vs 44 out of 100 had their tumour shrink with Sacituzumab govitecan compared with Chemotherapy (TPC); 4 more per 100.
- Roughly one extra person helped for every 25 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- Numbers are not recorded here for this endpoint. Sacituzumab govitecan: Immature at the primary analysis; crossover to sacituzumab permitted on progression.; Chemotherapy (TPC).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- Immature at the primary analysis; crossover to sacituzumab permitted on progression.
- These results apply to the people the trial enrolled: First-line metastatic TNBC, not candidates for PD-1 inhibitors: sacituzumab govitecan vs chemotherapy. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (PD-1); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
558 participants enrolled.
Immature at the primary analysis; crossover to sacituzumab permitted on progression.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR)primary | Sacituzumab govitecan | 279 | 9.7 months | 0.62 (0.5–0.77) | <0.0001 | link |
| Chemotherapy (TPC) | 279 | 6.9 months | ||||
| Objective response rate | Sacituzumab govitecan | — | 48% | — | — | — |
| Chemotherapy (TPC) | — | 44% | ||||
| Overall survival | Sacituzumab govitecan | — | Immature at the primary analysis; crossover to sacituzumab permitted on progression. | — | — | — |
| Chemotherapy (TPC) | — | — |
Pages like this
not linked directly; found by shared links- TrialASCENT
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan.
- TrialASCENT-04 / KEYNOTE-D19
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan.
- TrialTROPION-Breast02
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast05
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- TrialIZABRIGHT-Breast01
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Triple-negative breast cancer (TNBC).
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
- IdeaADC for residual disease after KEYNOTE-522
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
- IdeaTROP2 PET to choose and sequence TROP2 ADCs
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).